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KEY POINTS
 Although platelet transfusion thresholds have not changed, the demand for platelets has
increased, with most of the transfusions used in managing patients with hematologic
malignancies.
 Platelet products are prepared either by concentrating the platelets from whole-blood
donations (known as platelet concentrates [PCs]), or by collecting platelets directly from
donors via automated apheresis procedures (known as apheresis platelets [APs] or
single-donor platelets). APs are more widely used in the United States and have certain
advantages and drawbacks compared with PCs.
 Platelet transfusion guidelines have been published; however, they are not consistently
being followed, lack recommendations on some clinical scenarios, or differ in the platelet
threshold recommendations in some clinical settings.
 Platelet transfusion guidelines from different medical societies concur with strongly recommending prophylactic platelet transfusion in the setting of severe hypoproliferative
thrombocytopenia (10,000/mL) following chemotherapy or allogeneic bone marrow
transplant.
 Platelet transfusion decisions, whether for prophylactic or therapeutic indications, should
be weighed against the risks of transfusion side effects, refractoriness, contraindications
in some clinical settings, and platelet product availability.

INTRODUCTION

Platelets are commonly transfused blood components in many clinical settings, either
therapeutically to manage acute hemorrhage or prophylactically to prevent bleeding
when the platelet count decreases to less than a certain threshold or before a procedure. Platelets maintain hemostasis by controlling hemorrhage after blood vessel
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endothelial disruption. This process involves platelet adhesion, activation, and aggregation to form a platelet plug at the site of injury, thus maintaining vascular integrity.1
According to the American Red Cross, approximately 7000 units of platelets are
transfused daily in the United States.2 The demand for platelets has increased in spite
of the unchanging prophylactic platelet transfusion thresholds.3 Some factors that
could have contributed to the increase in platelet demand are a growth in the general
population, an increase in the incidence of hematologic malignancies in an aging population, and changing practices in managing hematologic malignancies.4 It is estimated that two-thirds of platelet components are used in managing patients with
hematologic malignancies.5
Some platelet transfusion guidelines have been developed6–8; however, platelet
transfusion practices are still heterogeneous because the available transfusion guidelines are not consistently followed and their implementation may be challenging in
some practices.9 In addition, these guidelines either lack recommendations or differ
in the platelet threshold recommendations in some clinical settings, such as surgery
and invasive procedures.6–8 When deciding on platelet transfusions, physicians are
encouraged to consider the possible adverse events of transfusion, and the costs
and labor associated with platelet acquisition. It is worth noting that platelet triaging
processes followed by blood banks to maintain an adequate inventory can sometimes
affect the decision to transfuse platelets. This article presents an update on platelet
transfusion, focusing on transfusion guidelines and platelet thresholds in different clinical settings.
PLATELET PRODUCTS

Platelet products are manufactured in 2 ways: concentrated and pooled from units of
whole blood (WB), or collected directly from donors via an automated apheresis
instrument.10
Platelet concentrates (PCs) are also known as random donor platelets or pooled
platelets. The number of platelets in each concentrate is variable, but 4 to 6 units of
PCs need to be pooled to provide a therapeutic dose of at least 3  1011 platelets
for adult patients. Apheresis platelets (APs) are also known as single-donor platelets.
A typical apheresis procedure often can collect sufficient platelets to be split into 2 or
even 3 doses of platelets, with each dose providing approximately the equivalent of 6
or more units of PCs (ie, 3–6  1011 platelets).11 APs are more widely used in the
United States and have certain advantages and drawbacks compared with PCs
(Table 1).
Pathogen Inactivation of Platelets

Despite increased laboratory testing and more stringent donor selection criteria,
transfusion-transmitted infections still occur. Current testing is not fully effective
against bacterial contamination, and septic transfusion reactions remain one of
the leading causes of transfusion-related mortality and serious adverse events.
The currently available testing also does not test for all potential pathogens, and
testing can only be implemented for new emerging pathogens after the agent has
been identified. As a strategy developed to not only proactively inactivate all the
pathogens that are the targets of current infectious disease testing of blood components but also inactivate all viruses, bacteria, and protozoa, pathogen inactivation
(PI) technologies significantly reduce the risks of transfusion-transmitted infections.
At present, three PI technologies of platelets are available, using amotosalen hydrochloride plus ultraviolet A light (INTERCEPT Blood System, Cerus Europe BV,
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Table 1
Advantages and disadvantages of platelet concentrates versus apheresis platelets
PCs

APs

Advantages

 Less costly
 Coproduct of WB collection
 Collection of WB and
concentration of platelets
easy to perform

 Single donor exposure per adult dose
 Donor matching (based on HLA, ABO
type, and so forth) possible
 Low RBC and WBC content
 Meets leukoreduction criteriaa
 Easier to perform bacterial testing
 Can be treated with FDA-approved
pathogen inactivation technology in
the United States

Disadvantages

 Must be pooled to provide
an adult dose
 Increased donor exposure
 Donor matching impractical
 Higher RBC and WBC content
 More labor intensive to
perform bacterial testing

 Expensive
 Collection requires dedicated
procedure, apheresis operator, and
instrument
 Time consuming and less convenient
for the donor

Abbreviations: FDA, US Food and Drug Administration; HLA, human leukocyte antigen; RBC, red
blood cell; WBC, white blood cell.
a
Integrated leukoreduction system is available on most instruments.

Amersfoort, The Netherlands), riboflavin plus ultraviolet light (Mirasol Pathogen
Reduction Technology, Terumo BCT Biotechnologies, Lakewood, CO), or ultraviolet
C light (Theraflex UV, MacoPharma, Mouvaux, France). All 3 achieve inactivation of a
broad range of pathogens by causing extensive photochemical damage to the
nucleic acids.12
The 3 different systems are in various stages of clinical use and regulatory approvals. At present, only the INTERCEPT technology is licensed in the United States
for APs. Both INTERCEPT and Mirasol are clinically available in Europe AP and PC
products, whereas the Theraflex UV system is still in development. The US Food
and Drug Administration (FDA) also approved the INTERCEPT technology as a safety
measure to reduce bacterial contamination of platelets, and, as such, a replacement
for both primary and secondary bacterial testing, including both culture-based and
rapid bacterial detection point-of-release tests (eg, Verax Platelet PGD Test System,
Verax Biomedical, Marlborough, MA).
PLATELET TRANSFUSION STRATEGIES: PROPHYLACTIC VERSUS THERAPEUTIC
Prophylactic Platelet Transfusion

Most platelet transfusions are given prophylactically to patients on chemotherapy,
following hematopoietic stem cell transplant, or before invasive procedures. Platelet
transfusion thresholds have been established by various medical societies (Table 2).
Hypoproliferative thrombocytopenia

Thrombocytopenia is a common problem in hematology and oncology patients.
Despite the major development of platelet growth factors and thrombopoietin molecules, platelet transfusions remain the most common treatment for patients with
thrombocytopenia.13 Most platelet components are transfused prophylactically to
prevent bleeding in the setting of hypoproliferative thrombocytopenia secondary to
bone marrow involvement with malignancy, or as a result of treatment mostly with
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Table 2
Prophylactic platelet transfusion thresholds according to different guidelines
Platelet Transfusion Threshold (Level of Evidence)
Indication/Procedure

AABB6

ASCO8

BSH7

Major surgery

<50,000/mL (WR)

<40,000–50,000/mL
(WR)

<50,000/mL (WR)

CNS or ophthalmic
surgery

NR

NR

<100,000/mL (WR)

Central venous
catheter placement

<20,000/mL (WR)

NR

<20,000/mL (SR)

Lumbar puncture

<50,000/mL (WR)

NR

<40,000/mL (WR)

Epidural or spinal
anesthesia

NR

NR

<80,000/mL (WR)

Bone marrow aspirate
or trephine biopsy

NR

NR

Platelet transfusion
not indicated (SR)

Percutaneous liver
biopsy

NR

NR

<50,000/mL (MR)

Hypoproliferative
thrombocytopenia
following
chemotherapy or
allogeneic BMT

10,000/mL (SR)

<10,000/mL (SR)

<10,000/mL (SR)

Hypoproliferative
thrombocytopenia
following autologous
BMT

NR

Platelet transfusion
not indicated (MR)

Platelet transfusion
not indicated (MR)

Chronic bone marrow
failure (including
patients
on low-dose oral
chemotherapy or
azacitidine)

NR

NR

Platelet transfusion
not indicated (MR)

Chronic bone marrow
failure on intensive
chemotherapy

NR

NR

<10,000/mL (SR)

Abbreviations: AABB, American Association of Blood Banks (former name); ASCO, American Society of Clinical Oncology; BMT, bone marrow transplant; BSH, British Society for Haematology; CNS,
central nervous system; NR, no recommendation is provided; MR, moderate recommendation; SR,
strong recommendation; WR, weak recommendation.

chemotherapy.4,5 The current evidence from published literature and guidelines supports prophylactic platelet transfusion in hypoproliferative thrombocytopenia.
The AABB (formerly known as the American Association of Blood Banks) strongly
recommends that hospitalized adult patients with therapy-induced hypoproliferative
thrombocytopenia should be transfused to reduce the risk of spontaneous bleeding.6
The AABB recommends transfusing with a single apheresis unit or equivalent when
the platelet count is less than or equal to 10,000/mL. The American Society of Clinical
Oncology (ASCO) shares the same platelet transfusion recommendation in this
setting.8 This recommendation applies to patients receiving intensive chemotherapy
or undergoing allogeneic stem cell transplant. The platelet count threshold is generally
increased to 15,000 or 20,000/mL when patients have risk factors of bleeding.9,14
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Fever, infection, and inflammation are among the risk factors of bleeding reported in
the literature9,15,16; however, studies are still warranted to identify these risk factors
and what platelet threshold should be the trigger for transfusion. Prophylactic platelet
transfusion to patients who had autologous stem cell transplant and are not bleeding
is not encouraged.17,18 Prophylactic platelet transfusion is not recommended for patients with chronic bone marrow failure (eg, myelodysplasia and aplastic anemia) even
if they are taking low-dose oral chemotherapy or azacitidine, whereas platelet transfusion is recommended for those receiving intensive chemotherapy.7
Before invasive procedures and surgery

Platelet threshold recommendations are variable for invasive procedures and surgeries. This recommendation relates to the lack of evidence and subsequently
the unavailability or weakness of platelet transfusion guidelines.6–8 The AABB,
ASCO, and the British Society for Haematology (BSH) agree on a platelet threshold
of 20,000/mL and 50,000/mL for central venous catheter placement and major nonneuraxial surgery, respectively. Although the available literature is low quality and
sparse, a platelet count more than 100,000/mL is usually recommended before
neurosurgery or ophthalmic surgery involving the posterior segment of the
eye.7,19,20 Evidence on platelet transfusion for lumbar puncture is weak without
any randomized clinical trials (RCT) to provide evidence.21 The AABB advocates
platelet transfusion for elective diagnostic lumbar puncture when the platelet count
is less than 50,000/mL.6 Despite lack of data, a platelet count of 80,000/mL is
considered safe for epidural or spinal anesthesia in the absence of bleeding risk
factors other than thrombocytopenia.22,23 Platelet transfusion is not indicated
before bone marrow aspirate or trephine biopsy because the risk of significant
bleeding is less than 0.1%7; bleeding can typically be stopped by applying pressure on the biopsy site.
Bronchoscopy with or without bronchoalveolar lavage can be safely performed in
patients with severe thrombocytopenia (platelet count of 10,000/mL).24,25 Endoscopic interventions are fairly safe in patients with platelet count greater than
50,000/mL. Nonetheless, a platelet count of greater than or equal to 20,000/mL might
be an appropriate threshold for platelet transfusion if a higher threshold is difficult to
attain.26,27 The data on percutaneous liver biopsy in patients with thrombocytopenia
are heterogeneous. However, knowing the low overall incidence of serious bleeding,
a platelet count of at least 50,000/mL is considered safe to perform percutaneous liver
biopsy.28
Therapeutic Platelet Transfusion

Clinically significant bleeding usually refers to bleeding that is more than skin bleeding
or epistaxis, and lasts more than 30 minutes, typically classified as World Health Organization (WHO) grade 2 or higher.29 Complicated by highly diverse and complex
clinical scenarios, variable definitions, and subjective assessment of bleeding, highquality evidence to guide platelet transfusion therapy in actively bleeding patients is
limited, and some variations in the recommendations of different guidelines are
unsurprising.
However, most consensus guidelines recommend a platelet count of less than
50,000/mL as the threshold for platelet transfusion in patients with major or severe
bleeding, including trauma,7,20,30–34 and disseminated intravascular coagulation
(DIC).35 Platelet count should be maintained at greater than 100,000/mL in the presence of multiple trauma, central nervous system (CNS), or ocular bleeding. The role
of therapeutic platelet transfusions in specific scenarios is discussed further here.
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Minor bleeding

Many minor bleeding (WHO grade 1) episodes consist of mucocutaneous hemorrhages that are limited in size and/or duration (eg, epistaxis <1 hour, petechial lesions
<2 mm in size, ecchymosis <10 cm in size), and often spontaneously resolve without
consequence. Data on the necessity and efficacy of platelet transfusions in minor
bleeding episodes are sparse. Although earlier studies showed that many severe
bleeding episodes were preceded by minor bleeding,36 recurrent event analysis of
data from the randomized TOPPS trial, which was a randomized controlled trial
comparing the use of prophylactic platelet transfusion with no prophylaxis in adult
thrombocytopenic patients with hematological malignancies, failed to show minor
bleeding as predictive for WHO grade 2 to 4 bleeding.16
The 2016 British Committee for Standards in Haematology (BCSH) guidelines
recommend that patients with WHO grade 1 bleeding and no additional risk factors
should be transfused if platelet count is less than 10,000/mL, the same as patients
without any bleeding. If the bleeding is more significant but not severe or life threatening, platelet transfusion can be considered if platelet count is less than 30,000/
mL.7 The benefits of platelet transfusion in patients with minor bleeding should be
weighed against the potential risks and evaluated along with alternative measures
such as antifibrinolytics, local measures at bleeding site, and close monitoring.
Trauma

Low platelet count has been correlated with increased morbidity and mortality in
massively transfused patients with trauma.37,38 However, platelet count may also be
less predictive of outcome in the trauma setting because of platelet dysfunction and
other coagulopathies.39 Consequently, the evidence to support particular thresholds
for platelet transfusion is weak.
The empiric administration of platelets in predefined ratios with other blood products in patients with trauma who are not necessarily thrombocytopenic is controversial, as well as the optimal ratio or timing. A meta-analysis40 and a systematic review41
of retrospective and observational studies showed improved survival among patients
with trauma receiving high platelet and plasma to red blood cell (RBC) ratios; however,
such data are subject to confounding factors such as survivorship bias. In contrast, a
review of 6 RCTs, 5 in patients with trauma, found no evidence of improved patient
mortality or morbidity when comparing transfusing at 1:1:1 plasma and platelet to
RBC ratio with a 1:1:2 ratio or standard care of primarily laboratory-guided transfusions.42 The current BCSH guidelines only recommend early use of platelets in addition to transfusion of plasma and RBCs at a 1:1 ratio in patients with trauma with, or at
risk of, massive bleeding.32
Disseminated intravascular coagulation (DIC)

The cornerstone of DIC treatment should be addressing the underlying cause. Platelet
transfusion in patients with DIC should be reserved for patients with active bleeding or
at high risk for bleeding (eg, postoperative, preinvasive procedure) to maintain the
platelet count greater than 50,000/mL. Transfusions should not be withheld for fear
of “fueling the fire” in such patients.
In nonbleeding patients with DIC, guidelines have recommended platelet count of
10,000 to 20,000/mL as the threshold for prophylactic platelet transfusion for patients
with no additional risk factors for significant bleeding.35,43
Intracerebral hemorrhage

Although most guidelines recommend maintaining the platelet count at greater than
100,000/mL in patients with CNS bleeding, data on the impact of platelet transfusion
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are overall limited. High-quality studies have mostly been focused on antiplatelet therapy (APT) –associated spontaneous intracerebral hemorrhage (sICH) and traumatic
intracerebral hemorrhage (tICH). Earlier cohort studies showed slightly, but not statistically significant, improved mortalities following platelet transfusion.44,45 However, in
the more recent, randomized controlled PATCH trial of 190 patients with APTassociated sICH,46 patients who received platelet transfusions were surprisingly
more likely to have poor outcomes and higher mortality at 3 months, as well as
increased hematoma growth at 24 hours. The mechanisms for the poorer outcomes
associated with platelet transfusion are unclear. The PATCH trial was critiqued for
low enrollment, stringent inclusion criteria, imbalance between the study arms, and
underrepresentation of patients requiring neurosurgical intervention.47 A separate
RCT of patients with APT-associated sICH who required neurosurgical intervention
showed that platelet transfusions were associated with a reduction of postoperative
hemorrhage and mortality from 34% to 15% at 6 months.48 For patients with APTassociated tICH, 2 recent systematic reviews and meta-analyses of mostly small
retrospective observational studies also failed to identify clear benefits of platelet
transfusion.49,50 In summary, the available data suggest that platelet transfusions
should be minimized in patients with APT-associated intracerebral hemorrhage
(ICH) but may be considered for the subset of patients requiring neurosurgical
intervention.
PLATELET TRANSFUSION IN SPECIFIC SETTINGS
Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is characterized by the presence of plateletspecific autoantibodies. Prophylactic platelet transfusion in ITP is not recommended.6
However, platelet transfusion can be considered before an invasive procedure or surgery when other treatments have failed. Administration of intravenous immunoglobulin
(IVIg) with platelets was shown to be associated with rapid restoration of adequate
platelet counts.51 However, platelet transfusion can have a role in serious bleeding.52
Posttransfusion purpura (PTP), which is considered a delayed transfusion reaction,
is a rare condition caused by antibodies against platelet-specific antigens. Sometimes
PTP results in significant bleeding, which can be fatal.53 Prophylactic platelet transfusion is not recommended in the setting of PTP, and management is based on IVIg.
Nevertheless, platelet transfusion is reserved for life-threatening bleeding.
Inherited and Acquired Platelet Disorders

Inherited platelet disorders are characterized by platelet dysfunction with or without
thrombocytopenia. The 2 described conditions are Bernard Soulier syndrome (BSS)
and Glanzmann thrombasthenia (GT). Antifibrinolytics and hormonal therapies are
usually the first-line treatment in managing bleeding diathesis in BSS and GT.54 However, platelet transfusion remains a common approach in managing major bleeding
and for prophylaxis. The risks of alloimmunization and platelet refractoriness should
be seriously entertained before platelet transfusion.54
Acquired platelet disorders are also characterized by platelet dysfunction caused by
platelet-extrinsic factors. Common clinical scenarios include drug-induced platelet
dysfunction, uremia, and trauma. There is weak evidence to support the use of platelet
transfusion to reverse APT. Platelet transfusion is contraindicated in APT-associated
ICH (discussed earlier in relation to ICH).46
Platelet dysfunction in uremia is multifactorial and includes abnormal platelet–vessel
wall interaction and platelet intrinsic defects.55 Platelet dysfunction should be
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corrected in patients with active bleeding or those who are planned for surgical procedures. Treatment options include correction of the underlying cause of uremia, dialysis, desmopressin, cryoprecipitate, or estrogen therapy.56
Platelet dysfunction can occur in trauma-induced coagulopathy even with a normal
platelet count.57 There is evidence that platelet transfusion in patients with trauma improves outcome.58 Massive transfusion protocols are a clear example of this practice.
PLATELET TRANSFUSION IN PEDIATRIC PATIENTS

The normal platelet count of a healthy newborn is the same as that of older children and
adults. In preterm neonates, the incidence of thrombocytopenia is inversely correlated
to the gestational age at birth; however, a clear relationship between thrombocytopenia
and clinically significant hemorrhage has not been established.59 Evidence-based
guidelines for optimal platelet transfusion are lacking in pediatric patients, and recommended transfusion thresholds for term infants and older children are primarily based
on those for adults, with additional safety margins built-in for preterm infants, higherrisk patients, or clinical scenarios based on local norms and expert opinions.60,61 Not
surprisingly, large variations and ambiguities exist in transfusion practices.62,63
For example, most institutions use a platelet count of 50,000 to 100,000/mL as the
transfusion threshold for neonates on extracorporeal membrane oxygenation because
of the higher bleeding risks,64,65 but there are no data from RCTs examining the efficacy and safety of the different thresholds. Another recommendation based on guidelines for adults is the threshold of platelet count less than 50,000/mL before lumbar
puncture.6,60,61 However, some investigators have suggested using 100,000/mL in
the presence of circulating blasts or a traumatic lumbar puncture.66,67
Premature neonates are at higher risks of intraventricular hemorrhage, therefore a
platelet count of 50,000/mL has commonly been used as the prophylactic transfusion
threshold.61 However, a recent multicenter, randomized trial supports a more restrictive transfusion trigger, because higher rates of death and major bleeding within
28 days were found among infants transfused at the higher (50,000/mL) than at the
lower (25,000/mL) threshold.68
In addition, recent subanalyses of data from the PLADO study highlighted some critical differences between pediatric and adult patients, and the limitations of extrapolating transfusion guidelines from the adult population. The study included 200
children who were randomized along with adults to prophylactically receive a low
(1.1  1011/m2 of body surface area), medium (2.2  1011/m2), or high (4.4  1011/
m2) platelet dose when the platelet count was less than 10,000/mL. There was no association between the platelet dose and bleeding for any age group, but pediatric patients overall had significantly higher incidence of WHO grade 2 or higher bleeding,
which also occurred over a wider range of platelet counts compared with adults,69
suggesting that factors other than thrombocytopenia likely affect the bleeding risks
more in children.
PLATELET TRANSFUSION REFRACTORINESS

Platelet transfusion refractoriness (PTR) has been studied well in the literature and
continues to be a challenge; it is associated with increased morbidity and mortality.70
Nonimmune causes comprise around 80% of the causes of PTR, and these include
fever, infection, DIC, bleeding, splenic sequestration, bone marrow failure, and certain
medications.71 Development of antibodies to class I human leukocyte antigens (HLAs)
or, less frequently, antibodies to human platelet–specific antigens (HPAs) represent
around one-third of refractory cases.72 When platelet increments are not satisfactory,
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ABO-identical platelets should be used because the A and B antigens can be
adsorbed to platelets, thus ABO incompatibility can contribute to increased platelet
clearance from the circulation. Immune-mediated PTR can be shown by failure of
an adequate corrected count increment (<5000/mL) 10 to 60 minutes following ABOcompatible platelet transfusion on 2 consecutive occasions.73,74 It is worth mentioning
that patients with class I HLA antibodies do not necessarily develop PTR. Patients who
are refractory to platelet transfusions and have class I HLA antibodies should receive
HLA-matched/HLA-compatible platelet transfusion. If patients continue to be refractory to HLA-matched/HLA-compatible platelet transfusion and have HPA antibodies,
they should receive HPA-matched platelet transfusion.7 In clinical practice, finding
compatible platelet units can be challenging for highly alloimmunized patients.
CONTRAINDICATIONS TO PLATELET TRANSFUSIONS

Platelet transfusion practices and their association with thrombosis and mortality were
evaluated in ITP, thrombotic thrombocytopenic purpura (TTP), and heparin-induced
thrombocytopenia (HIT) by Goel and colleagues.75 The study included hospitalizations
of 79,980 patients with ITP, 10,624 patients with TTP, and 6332 patients with HIT.
There were no significant associations between platelet transfusion and thrombosis/
mortality in ITP. Platelet transfusions were associated with arterial thrombosis and
mortality among patients with TTP and HIT. Platelet transfusions are contraindicated
in TTP and HIT unless there is life-threatening bleeding.7,76
SUMMARY

Platelets are commonly transfused either therapeutically to manage bleeding or prophylactically to prevent bleeding. Platelet transfusion practices are heterogeneous,
although platelet transfusion guidelines have been published from different societies. In some clinical settings, these guidelines do not agree on the same platelet
transfusion threshold. Moreover, the recommendations are either weak or lacking
in many clinical situations. Platelet transfusion decisions should be weighed against
the risks of transfusion side effects, refractoriness, and contraindications, as in TTP
and HIT.
CLINICS CARE POINTS

 Platelet products are prepared either by concentrating the platelets from whole blood
donations, or more commonly by collecting platelets directly from donors via automated
apheresis procedures.
 Published platelet transfusion guidelines partly lack recommendations or differ in the
platelet threshold recommendations in some clinical situations.
 Platelet transfusion guidelines concur with strongly recommending prophylactic platelet
transfusion for severe hypoproliferative thrombocytopenia ( 10,000/mL) following
chemotherapy or allogeneic bone marrow transplantation.
 Platelet transfusion decisions should be weighed against the risks of transfusions and the
availability of platelet products.
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